Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation

Oncogene volume 31, pages 992–1000 (2012)Cite this article

Abstract

We have previously described InvEE transgenic mice in which non-dividing, differentiating epidermal cells express oncogenically activated MAPK kinase 1 (MEK1). Skin wounding triggers tumour formation in InvEE mice via a mechanism that involves epidermal release of IL-1α and attraction of a pro-tumorigenic inflammatory infiltrate. To look for potential effects on the underlying connective tissue, we screened InvEE and wild-type epidermis for differential expression of cytokines and immune modulators. We identified a single protein, CD26 (dipeptidyl peptidase-4). CD26 serum levels were not increased in InvEE mice. In contrast, CD26 was upregulated in keratinocytes expressing mutant MEK1 and in the epithelial compartment of InvEE tumours, where it accumulated at cell–cell borders. CD26 expression was increased in dermal fibroblasts following skin wounding but was downregulated in tumour stroma. CD26 activity was stimulated by calcium-induced intercellular adhesion in keratinocytes, suggesting that the upregulation of CD26 in InvEE epidermis is due to expansion of the differentiated cell layers. IL-1α treatment of dermal fibroblasts stimulated CD26 activity, and therefore epidermal IL-1α release may contribute to the upregulation of CD26 expression in wounded dermis. Pharmacological blockade of CD26, via Sitagliptin, reduced growth of InvEE tumours, while combined inhibition of IL-1α and CD26 delayed tumour onset and reduced tumour incidence. Our results demonstrate that inappropriate activation of MEK1 in the epidermis leads to changes in dermal fibroblasts that, like the skin inflammatory infiltrate, contribute to tumour formation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E et al. (2004). N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci 13: 145–154.

    Article  CAS  Google Scholar 

  • Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J et al. (2009). Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 47: 253–261.

    Article  CAS  Google Scholar 

  • Arwert EN, Lal R, Quist S, Rosewell I, van Rooijen N, Watt FM . (2010). Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate. Proc Natl Acad Sci USA 107: 19903–19908.

    Article  CAS  Google Scholar 

  • Cordero OJ, Salgado FJ, Nogueira M . (2009). On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 58: 1723–1747.

    Article  CAS  Google Scholar 

  • Deacon CF . (2007). Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs 16: 533–545.

    Article  CAS  Google Scholar 

  • Egeblad M, Nakasone ES, Werb Z . (2010). Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18: 884–901.

    Article  CAS  Google Scholar 

  • Fan H, Meng W, Kilian C, Grams S, Reutter W . (1997). Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. Eur J Biochem 246: 243–251.

    Article  CAS  Google Scholar 

  • Hobbs RM, Silva-Vargas V, Groves R, Watt FM . (2004). Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol 123: 503–515.

    Article  CAS  Google Scholar 

  • Iwata S, Morimoto C . (1999). CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med 190: 301–306.

    Article  CAS  Google Scholar 

  • Jackson EK, Mi Z . (2008). Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 51: 1637–1642.

    Article  CAS  Google Scholar 

  • Janes SM, Watt FM . (2006). New roles for integrins in squamous-cell carcinoma. Nat Rev Cancer 6: 175–183.

    Article  CAS  Google Scholar 

  • Jensen KB, Driskell RR, Watt FM . (2010). Assaying proliferation and differentiation capacity of stem cells using disaggregated adult mouse epidermis. Nat Protoc 5: 898–911.

    Article  CAS  Google Scholar 

  • Karlsson L, Bondjers C, Betsholtz C . (1999). Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle. Development 126: 2611–2621.

    CAS  PubMed  Google Scholar 

  • Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H et al. (2005). (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: 141–151.

    Article  CAS  Google Scholar 

  • Kohl A, Volk HD, Buntrock P, Kohl G, Diamantstein T, von Baehr R . (1991). The role of dipeptidylpeptidase IV positive T cells in wound healing and angiogenesis. Agents Actions 32: 125–127.

    Article  CAS  Google Scholar 

  • Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO et al. (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330: 827–830.

    Article  CAS  Google Scholar 

  • Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ . (2010). Metformin associated with lower cancer mortality in type 2 diabetes (ZODIAC-16). Diabet Care 33: 322–326.

    Article  CAS  Google Scholar 

  • Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR et al. (2005). Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 22: 654–657.

    Article  CAS  Google Scholar 

  • Maley F, Trimble RB, Tarentino AL, Plummer Jr TH . (1989). Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 180: 195–204.

    Article  CAS  Google Scholar 

  • Nemoto E, Sugawara S, Takada H, Shoji S, Horiuch H . (1999). Increase of CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon stimulation with cytokines and bacterial components. Infect Immun 67: 6225–6233.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Novelli M, Savoia P, Fierro MT, Verrone A, Quaglino P, Bernengo MG . (1996). Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol 134: 1052–1056.

    Article  CAS  Google Scholar 

  • Ohnuma K, Dang NH, Morimoto C . (2008). Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 29: 295–301.

    Article  CAS  Google Scholar 

  • Owens DM, Watt FM . (2003). Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer 3: 444–451.

    Article  CAS  Google Scholar 

  • Pereira DA, Gomes L, El-Cheikh MC, Borojevic R . (2003). Dipeptidyl peptidase IV (CD26) activity in the hematopoietic system: differences between the membrane-anchored and the released enzyme activity. Braz J Med Biol Res 36: 567–578.

    Article  CAS  Google Scholar 

  • Reinhold D, Vetter RW, Mnich K, Buhling F, Lendeckel U, Born I et al. (1998). Dipeptidyl peptidase IV (DP IV, CD26) is involved in regulation of DNA synthesis in human keratinocytes. FEBS Lett 428: 100–104.

    Article  CAS  Google Scholar 

  • Romero MR, Carroll JM, Watt FM . (1999). Analysis of cultured keratinocytes from a transgenic mouse model of psoriasis: effects of suprabasal integrin expression on keratinocyte adhesion, proliferation and terminal differentiation. Exp Dermatol 8: 53–67.

    Article  CAS  Google Scholar 

  • Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y . (2010). DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 213: 429–435.

    Article  CAS  Google Scholar 

  • Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C . (2010). Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 401: 7–12.

    Article  CAS  Google Scholar 

  • Vivier I, Marguet D, Naquet P, Bonicel J, Black D, Li CX et al. (1991). Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol 147: 447–454.

    CAS  PubMed  Google Scholar 

  • Watt FM . (1984). Selective migration of terminally differentiating cells from the basal layer of cultured human epidermis. J Cell Biol 98: 16–21.

    Article  CAS  Google Scholar 

  • Willheim M, Ebner C, Baier K, Kern W, Schrattbauer K, Thien R et al. (1997). Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol 100: 348–355.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Donna Michelle Smith for performing SG chromatography. We acknowledge support from Cancer Research UK, the Dutch Cancer Society (to RM), the Wellcome Trust, the MRC, the European Union, Hutchison Whampoa and Cambridge University.

Author information

Author notes

  1. E N Arwert and R A Mentink: These authors are joint first authors.

Authors and Affiliations

  1. Cancer Research UK Cambridge Research Institute, Cambridge, UK

    E N Arwert, R A Mentink, E Hoste, S J Goldie, S Quist & F M Watt

  2. Wellcome Trust Centre for Stem Cell Research, Cambridge, UK

    R R Driskell & F M Watt

Authors
  1. E N Arwert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R A Mentink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R R Driskell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Hoste
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S J Goldie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Quist
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F M Watt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F M Watt.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arwert, E., Mentink, R., Driskell, R. et al. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene 31, 992–1000 (2012). https://doi.org/10.1038/onc.2011.298

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.298

Keywords

This article is cited by

Search

Advanced search

Quick links